183 related articles for article (PubMed ID: 26663264)
1. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
2. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
4. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Norkin M; Chang M; An Q; Leather H; Katragadda L; Li Y; Moreb JS; May WS; Brown RA; Hsu JW; Hiemenz JW; Wingard JR; Cogle CR
Leuk Res; 2016 Jul; 46():69-73. PubMed ID: 27132034
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
Pullarkat V; Aldoss I
Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
[TBL] [Abstract][Full Text] [Related]
6. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
Cancer; 2012 Nov; 118(21):5278-82. PubMed ID: 22517268
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients.
El Gammal MM; Owaidat HM; Rashed RA; Fatah RA; Samra MA
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e406-e413. PubMed ID: 31031147
[TBL] [Abstract][Full Text] [Related]
8. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
[TBL] [Abstract][Full Text] [Related]
9. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
10. Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort.
England JT; Saini L; Hogge D; Forrest D; Narayanan S; Power M; Nevill T; Kuchenbauer F; Hudoba M; Szkotak A; Brandwein J; Sanford D
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e427-e436. PubMed ID: 32201130
[TBL] [Abstract][Full Text] [Related]
11. [The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].
Jia JS; Yang SM; Wang J; Jiang H; Zhao T; Bao L; Shi HX; Lu J; Zhu HH; Lai YY; Jiang B; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):497-502. PubMed ID: 27431075
[TBL] [Abstract][Full Text] [Related]
12. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
13. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
[TBL] [Abstract][Full Text] [Related]
14. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy.
Souto Filho JT; Loureiro MM; Pulcheri W; Morais JC; Nucci M; Portugal RD
Diagn Pathol; 2015 Jul; 10():122. PubMed ID: 26205005
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
17. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
18. [A new prognostic stratification for patients with acute myeloid leukemia].
Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
[TBL] [Abstract][Full Text] [Related]
19. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
Reagan JL; Sullivan MR; Winer ES; Lansigan F; Cardin MS; Castillo JJ
Leuk Res; 2015 Aug; 39(8):812-7. PubMed ID: 26045177
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
